Phentolamine · Oraverse, Regitine

What is Phentolamine?

Phentolamine is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist that reversibly binds alpha-1 receptors on the iris dilator muscle, reducing pupil diameter. It is studied in night vision disturbances, presbyopia and mesopic vision problems, and is labeled for reversing pharmacologically induced mydriasis and soft-tissue anesthesia of the lip and tongue after intraoral local anesthetic injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Oraverse, Regitine, Ryzumvi

Drug type

Small molecule

Targets

alpha-1 adrenergic receptor, alpha-2 adrenergic receptor

Mechanism

Antagonist of alpha-1 adrenergic receptor and alpha-2 adrenergic receptor

Pathways

adrenergic signaling, iris dilator muscle contraction, pupil dilation

Therapy area

Ophthalmology

Developer

Novartis

In trials of

IRD

FDA status

Approved as Oraverse, Regitine, Ryzumvi (January 30, 1952), NDA008278 · FDA label

UNII

Z468598HBV

✅ FDA-approved uses

• Pharmacologically-induced mydriasis (Ryzumvi)
• Reversal of soft-tissue anesthesia (Oraverse)

From the indications section of the FDA label (version of Mar 15, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Vision DisordersVision Loss NightDecrease in Night VisionDim Light Vision DisturbancesDisturbance; Vision, LossMesopic VisionNight Vision ComplaintsNight Vision LossPresbyopia

Sources

• FDA label (DailyMed)
• FDA label Ryzumvi (2026-03-15), indications
• FDA label Oraverse (2018-12-05), indications
• ClinicalTrials.gov NCT01703559
• ClinicalTrials.gov NCT01703559
• ClinicalTrials.gov NCT04004507
• ClinicalTrials.gov NCT04638660

Updated Oct 11, 2026.